Healthcare Industry News: Decapeptyl
News Release - May 27, 2014
Orient EuroPharma and Debiopharm Group(TM) Announce Their Partnership and the Launch of Pamorelin(R) LA in SingaporeSINGAPORE and LAUSANNE, Switzerland, May 27, 2014 -- (Healthcare Sales & Marketing Network) -- Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines with a strong sales network of 360 dedicated and experienced sales representatives and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs along with companion diagnostics jointly announce the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia. Today, Orient EuroPharma and Debiopharm announce the launch of Pamorelin® in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.
Mr.JP. Chang, President of Pharmaceutical Business Unit, Orient EuroPharma said that "it is great to cooperate with Debiopharm Group™ for introducing the new drug to South East Asian territories. Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients".
"This collaboration opens up an important new market for our backbone therapy of advanced prostate cancer (locally advanced and metastatic)" said Thierry Mauvernay, Delegate of the Board, Debiopharm Group. "After successful launch in 74 countries, we look forward to bringing Pamorelin® to several South East Asian markets, together with Orient EuroPharma".
About Pamorelin® LA (active ingredient: triptorelin)
Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). Debiopharm has developed three sustained-release formulations (1, 3 and 6 months) of triptorelin pamoate. The 1- and 3-month formulations have already been registered in numerous countries and are available under different brand names: Trelstar®, Decapeptyl® and Pamorelin®. The 6-month formulation has been registered and is available in Singapore, Europe and the US.
About Orient EuroPharma
Orient EuroPharma Co., Ltd. (OEP) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong, Malaysia, Singapore, Philippines, and a strong sales network of 360 dedicated and experienced sales representatives. Established in 1982, the Orient EuroPharma Group officially started trade in the GTSM in Taiwan in 2003. Main products are pharmaceuticals, cancer drugs, cosmeceuticals, infant and adult nutrition and healthcare products. The Group owns eight subsidiaries located in China, Southeast Asia and United States, and more than 760 employees globally. In 2008, it established Orient PHARMA focusing on new drugs development, which includes a new pharmaceutical plant and has obtained Taiwan FDA PIC/S GMP Certificate in 2011 and U.S. FDA CGMP Certificate in 2013. OEP co-op with NanoCarrier Co. Ltd, and jointly invested in construction of a new Taiwan pharmaceutical plant for injectable cancer drugs in 2012, making it one of the few companies that can vertically integrate drug research and development, manufacture, marketing and channel management. For more information, please visit http://www.oep.com.tw.
About Debiopharm Group™
Debiopharm Group™ is a Swiss-based global biopharmaceutical group of 4 companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments.
Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.
For more information about Debiopharm Group™, please visit: http://www.debiopharm.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.